6. Bamlanivimab wins EUA for patients at risk of severe COVID-19 infections
Developer: Eli Lilly (NYSE:LLY)
Description: Bamlanivimab (LY-CoV555) is a monoclonal antibody intended to treat mild-to-moderate COVID-19 in patients at risk of severe infections.
Development status: LY-CoV555 won an EUA from the FDA on Nov. 2020. In early December, Eli Lilly announced that it was launching a trial with UnitedHealth to test the antibody in high-risk patients.
HHS is working with Eli Lilly, its distributor AmerisourceBergen and local government health departments to distribute bamlanivimab. Image courtsey of the U.S. Department of Health and Human Services.
CVS Health (NYSE:CVS), the parent of CVS Pharmacy, is working with the U.S. government to administer the monoclonal antibody.
Tell Us What You Think!
You must be logged in to post a comment.